Business Description
Tvardi Therapeutics Inc
NAICS : 541713
SIC : 2833
ISIN : US1407553072
Total Employee Number:
12Description
Tvardi Therapeutics Inca clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with unmet need. Its pipeline includes two oral, small molecule STAT3 inhibitors: TTI-101 and TTI-109. TTI-101 is its first-generation direct STAT3 inhibitor, currently in Phase 1b/2 clinical development in hepatocellular carcinoma (HCC). TTI-109 is a phosphate prodrug of TTI-101 that is mechanistically identical to its parent molecule but is designed to enhance its ability to target STAT3.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 143.57 | |||||
Equity-to-Asset | 0.56 | |||||
Debt-to-Equity | 0.01 | |||||
Debt-to-EBITDA | -0.01 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | N/A/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 24.5 | |||||
3-Year EPS without NRI Growth Rate | 25.8 | |||||
3-Year FCF Growth Rate | 24.3 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 45.71 | |||||
9-Day RSI | 50 | |||||
14-Day RSI | 50.3 | |||||
3-1 Month Momentum % | -23.05 | |||||
6-1 Month Momentum % | -40.8 | |||||
12-1 Month Momentum % | -89.77 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.25 | |||||
Quick Ratio | 2.25 | |||||
Cash Ratio | 2.22 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -0.1 | |||||
Shareholder Yield % | 53.35 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -87.55 | |||||
ROA % | -42.98 | |||||
ROIC % | -679.8 | |||||
3-Year ROIIC % | -2777.5 | |||||
ROC (Joel Greenblatt) % | -1013.6 | |||||
ROCE % | -109.55 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 2.07 | |||||
Price-to-Tangible-Book | 2.13 | |||||
EV-to-EBIT | -0.18 | |||||
EV-to-Forward-EBIT | -0.08 | |||||
EV-to-EBITDA | -0.18 | |||||
EV-to-Forward-EBITDA | -0.08 | |||||
EV-to-FCF | -0.24 | |||||
| Price-to-Net-Current-Asset-Value | 2.15 | |||||
| Price-to-Net-Cash | 2.2 | |||||
Earnings Yield (Greenblatt) % | -555.56 | |||||
FCF Yield % | -71.96 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:TVRD
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Tvardi Therapeutics Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -3.1 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 108.38 | ||
| 14-Day RSI | 50.3 | ||
| 14-Day ATR ($) | 0.581409 | ||
| 20-Day SMA ($) | 2.67325 | ||
| 12-1 Month Momentum % | -89.77 | ||
| 52-Week Range ($) | 1.5 - 43.65 | ||
| Shares Outstanding (Mil) | 9.38 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9999 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Tvardi Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Tvardi Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-13 | In 120 days | ||
| Second quarter earnings results for 2026 | 2026-08-14 | In 29 days | ||
| General meeting for 2026 | 2026-06-09 12:00 | 2.85 (-6.56%) | ||
| Raymond James BioPharma CEO Strategy Series | 2026-06-05 10:00 | 3.08 (+4.05%) | ||
| Jefferies Global Healthcare Conference | 2026-06-04 08:10 | 2.95 (-6.35%) | ||
| First quarter earnings results for 2026 | 2026-05-08 | 4.21 (+14.71%) | ||
| Annual report for 2025 | 2026-03-31 | 3.20 (+4.07%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-31 | 3.20 (+4.07%) | ||
| Barclays 28(th) Annual Global Healthcare Conference | 2026-03-10 14:00 | 3.98 (+2.05%) | ||
| TD Cowen 46(th) Annual Health Care Conference | 2026-03-03 13:50 | 3.96 (-0.25%) |
Show
Entries
Tvardi Therapeutics Inc Frequently Asked Questions
What is Tvardi Therapeutics Inc(TVRD)'s stock price today?
The current price of TVRD is $3.21. The 52 week high of TVRD is $43.65 and 52 week low is $1.50.
When is next earnings date of Tvardi Therapeutics Inc(TVRD)?
The next earnings date of Tvardi Therapeutics Inc(TVRD) is 2026-08-14 Est..
Does Tvardi Therapeutics Inc(TVRD) pay dividends? If so, how much?
Tvardi Therapeutics Inc(TVRD) does not pay dividend.
Guru Commentaries on NAS:TVRD
No articles.
Press Release
Articles on Tvardi Therapeutics Inc
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers